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A B S T R A C T
Introduction and Aim. About 3 million men take testosterone in the United States with many reproductive-age men
unaware of the negative impact of testosterone supplementation on fertility. Addressing this population, we provide
an early report on the use of human chorionic gonadotropin (HCG)-based combination therapy in the treatment of
a series of men with likely testosterone-related azoospermia or severe oligospermia.
Methods. We retrospectively reviewed charts from two tertiary care infertility clinics to identify men presenting with
azoospermia or severe oligospermia (<1 million sperm/mL) while taking exogenous testosterone. All were noted to
have been placed on combination therapy, which included 3,000 units HCG subcutaneously every other day
supplemented with clomiphene citrate, tamoxifen, anastrozole, or recombinant follicle-stimulating hormone (or
combination) according to physician preference.
Main Outcome Measure. Clinical outcomes, including hormone values, semen analyses, and clinical pregnancies,
were tracked.
Results. Forty-nine men were included in this case series. Return of spermatogenesis for azoospermic men or improved
counts for men with severe oligospermia was documented in 47 men (95.9%), with one additional man (2.1%) having a
documented pregnancy without follow-up semen analysis. The average time to return of spermatogenesis was 4.6 months
with a mean first density of 22.6 million/mL. There was no significant difference in recovery by type of testosterone
administered or supplemental therapy. No men stopped HCG or supplemental medications because of adverse events.
Conclusions. We here provide an early report of the feasibility of using combination therapy with HCG and
supplemental medications in treating men with testosterone-related infertility. Future discussion and studies are
needed to further characterize this therapeutic approach and document the presumed improved tolerability and
speed of recovery compared with unaided withdrawal of exogenous testosterone.Wenker EP, Dupree JM, Langille
GM, Kovac J, Ramasamy R, Lamb D, Mills JN, and Lipshultz LI. The use of HCG-based combination
therapy for recovery of spermatogenesis after testosterone use. J Sex Med 2015;12:1334–1337.
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Introduction and Aims
Testosterone supplementation therapy (TST)use among men of reproductive years is
becoming increasingly common, with an estimated
3 million men on TST in the United States [1].
Exogenous testosterone use can result in sterility
because of suppression of the hypothalamic–
pituitary–gonadal axis with resulting decreased
follicle-stimulating hormone (FSH) and luteinizingFinancial Support: None.
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hormone (LH) release from the anterior pituitary
[2]. Low levels of LH lead to decreased
intratesticular testosterone production by Leydig
cells. This decreased testosterone level, coupled
with reduced Sertoli cell function from blunted
FSH secretion causes diminished spermatogenesis
in the seminiferous tubules [3]. Many men are
unaware of this side effect and present for infertility
evaluations while on TST [4].
No consensus currently exists on the optimal
treatment regimen for men with TST-induced
infertility. While previous studies suggested pos-
sible irreversible damage to spermatogenesis due to
TST, a recent meta-analysis showed no permanent
loss of spermatogenesis in men previously on TST
[5]. However, recoverymay take a year ormore and
sperm production may not return to pretreatment
levels. In addition, sudden withdrawal of TST
renders patients symptomatically hypogonadal
until endogenous testosterone production returns
to normal levels. Ideally, therapy would support
return of spermatogenesis quickly with minimal
side effects. As such, human chorionic gonadotro-
pin (HCG) is a particularly promising medication
because of its ability to raise suppressed serum and
intratesticular testosterone levels that are necessary
for normal spermatogenesis [6].
Here we present a preliminary, observational
report of the use of HCG-based combination
therapy in the treatment of men with TST-related
infertility.
Methods and Main Outcome Measures
Patient Selection
Men presenting for infertility evaluations while on
TST from 2006 to 2013 were retrospectively iden-
tified from medical records at two andrology
clinics in Texas and Colorado. All patients received
a complete infertility evaluation by fellowship-
trained andrologists. Patients were included in the
analysis if they were using testosterone at initial
evaluation and had a semen analysis demonstrating
azoospermia or severe oligospermia (density <1
million/mL). Men were excluded if they had a
history of surgical or congenital sterilization (i.e.,
vasectomy or congenital absence of the vas defer-
ens), refused to stop TST, or did not have available
follow-up semen analyses or pregnancy data after
starting HCG. Relevant TST information was
extracted from the charts, including modality
(injectable, transdermal, pellet, or unknown) and
duration of use.
HCG-Based Intervention
At the initial evaluation, all men stopped TST and
began a combination regimen with 3,000 HCG
units administered subcutaneously every other day
as primary therapy. This dose and interval were
chosen to accommodate the half-life of HCG
(approximately 33 hours), aiming to provide
patients with relatively stable HCG levels. HCG
therapy was supplemented with clomiphene
citrate, tamoxifen, anastrozole, or recombinant
FSH (or a combination) according to physician
preference and clinical situation. The supplemen-
tal therapies were added to raise native FSH
levels, as HCG does not raise FSH levels and has
no activity on FSH receptors. Semen and
hormone analyses were performed after 4 weeks
of HCG therapy and monthly thereafter until
semen parameters became stable or a pregnancy
was achieved.
End Points
The primary end point was recovery of any sperm
in the ejaculate in men who were azoospermic or
an increase in density in those who were severely
oligospermic. Achieving a documented pregnancy
was a secondary end point. Data were analyzed
using Student’s t-tests and chi-squared tests with a
significance value of P < 0.05. The Baylor College
of Medicine Institutional Review Board approved
the study.
Results
Forty-nine men, aged 27 to 63 (mean 40.5,
median 40), were identified. Forty-five (91.8%)
were azoospermic at presentation; the remaining
four (8.2%) were severely oligospermic. These
men had been using TST for an average of 52.4
months prior to initiating HCG-based combina-
tion therapy. Sixteen (32.7%) had used injectable
testosterone, 16 (32.7%) had used transdermal
testosterone, 7 (14.3%) used pellets, 6 (12.2%)
used some combination of the three, and 4 (8.2%)
used unknown types of TST. All were placed on
3,000 units HCG every other day after discon-
tinuing TST. For supplemental medications, 35
(71.4%) were prescribed clomiphene citrate, 28
(57.1%) were prescribed tamoxifen, 10 (20.4%)
were prescribed anastrozole, and 1 (2.0%) was
prescribed recombinant FSH. The mean duration
of HCG-based combination therapy was 14
months. The mean initial FSH, LH, and testos-
terone levels in subjects prior to stopping TST
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were 1.39 mIU, 0.85 mIU, and 573.5 ng/dL,
respectively. The mean duration of follow-up was
14 months and 686 total months for the entire
cohort.
After starting HCG-based therapy, return of
spermatogenesis or improvement in sperm density
>1 million/mL was documented in 47 (95.9%)
men. One additional man reported a pregnancy
but did not have a semen analysis performed.
Including this individual, 98.0% of men were able
to recover spermatogenesis. The average time
to first sperm recovery in the ejaculate (for
azoospermic men) or improvement above 1
million/mL (for severely oligospermic men) was
4.6 months; the mean first sperm density was 22.6
million/mL. At this milestone, the average FSH
level was 4.04 mIU, an increase of 191% over the
initial value. Similarly, the average LH level was
3.12 mIU, an increase of 267%. Average testoster-
one levels were 475.8 ng/dL when sperm first
returned to the ejaculate, a 17.0% decrease from
levels achieved while on TST (573.5 ng/dL,
P = 0.11).
As seen in Table 1, there were no significant
differences in mean time to first sperm recovery
based on type of TST used (injection, 4.4 months;
transdermal, 4.4 months; pellet, 3.4 months; com-
bination, 6.2 months; P = 0.72) or type of supple-
mental therapy used (clomiphene, 3.2 months;
tamoxifen, 4.1 months; anastrozole, 7.5 months;
mixed, 5.5; P = 0.14).
Nineteen men (38.8%) achieved a clinically
documented pregnancy during the mean 14
months of follow-up, with no significant difference
by type of TST or supplemental therapy used. No
men discontinued therapy because of adverse
effects.
Discussion
This early observational report suggests that
using HCG-based therapy supplemented with
clomiphene citrate, tamoxifen, anastrozole, or a
combination can be used to quickly restore sper-
matogenesis in individuals with azoospermia or
severe oligospermia because of previous TST.
The return of, or improvements in, spermatogen-
esis was independent of the type of testosterone
used and did not vary significantly based on type
of supplemental therapy.
Previous studies have demonstrated that HCG
administration can increase intratesticular testos-
terone levels to normal concentrations, but the
drug has not been studied in this current context.6
We postulate that supplemental medications are
necessary to support FSH production, which
cannot be accomplished with HCG alone, and clo-
miphene citrate and tamoxifen have been shown to
increase both gonadotropins [7].
There are currently no studies on the natural
history of unassisted sperm recovery after pro-
longed testosterone use. Some estimates could be
derived from the male contraception literature but
it is important to consider that patients in the male
contraception studies were treated in the closely
monitored context of a clinical trial and used tes-
tosterone for a maximum of 18 months, making
them an unrealistic comparison group. Neverthe-
less, in an analysis of World Health Organization
studies where testosterone was used for 18 months
or less to induce contraceptive infertility, recovery
of sperm concentration to >20 million/mL took an
average of 3.2 months [8]. Our study showed
similar recovery times in a clinical environment
where patients had been using TST for an average
Table 1 Testosterone (T) levels and time to sperm recovery for infertile men (n = 49) presenting on various types of
testosterone therapy
n Age* (SD)
Mean
testosterone†
prior to HCG
therapy (SD)
Mean
testosterone†
while on HCG
therapy (SD)
Mean time (months)
to first sperm
recovery‡
or improvement§
Testosterone
therapy
Injection 16 41.3 (9.0) 610 (398) 542 (244) 4.4 (4.2)
Transdermal 16 39.0 (6.5) 645 (288) 447 (137) 4.4 (5.0)
Pellet 7 43.9 (9.5) 498 (324) 465 (215) 3.4 (1.3)
Combination 6 42.8 (3.3) 503 (442) 399 (127) 6.2 (3.4)
Unknown 4 33.5 (4.7) 378 (177) 475 (213) 5.7 (3.1)
ANOVA P value 0.25 0.66 0.63 0.78
*In years
†In ng/dL
‡For men initially azoospermic
§For men initially severely oligospermic
ANOVA, analysis of variance; HCG, human chorionic gonadotropin; SD, standard deviation
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of 52 months and did so without patients experi-
encing decreases in testosterone levels.
This HCG-based combination regimen has a
number of advantages, including its use of estab-
lished (albeit off-label), well-toleratedmedications.
Additionally, this regimen accomplishes the goal of
inducing a speedy recovery of spermatogenesis.
However, this study’s single-arm, observational,
and retrospective nature makes definitive proof of
this HCG-based combination therapy’s efficacy
impossible to prove. Future studies should focus on
comparing this combination regimen with HCG
monotherapy, oral monotherapy, and unaided tes-
tosterone cessation, as well as the ability ofHCG to
mitigate hypogonadal symptoms associated with
abrupt discontinuation of TST.
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